Longevity Health Stock Price, News & Analysis

Longevity Health Holdings, Inc. (associated with the warrant ticker XAGEW) is a company focused on human longevity and healthy aging. According to its public disclosures, the business centers on applying scientific advances in regenerative bio‑aesthetics, diagnostics, and nutrition to help people look and feel their best at any age.

In its bio‑aesthetics activities, Longevity Health Holdings highlights two regenerative technologies for skin and hair health: Carmell Secretome™ and Elevai Exosomes™. Company materials describe Carmell Secretome™ as a blend of growth factors, proteins, peptides and bio‑lipids derived from allogeneic human platelets, which are identified as the body’s principal cells responsible for healing and regeneration. Elevai Exosomes™ are described as being derived from human umbilical mesenchymal stem cells and noted as containing a greater number of proteins than exosomes from non‑stem cell sources.

Beyond aesthetics, Longevity Health Holdings has articulated a broader strategy around diagnostics and healthy aging. Through merger agreements and business updates, the company has described an intention to build a footprint in diagnostics for early detection and proactive management of chronic disease risk, and to connect these diagnostics with its bio‑aesthetic products and contemplated expansion into nutrition under the banner "Healthy Aging, Inside and Out™." This strategy has included a merger agreement with 20/20 BioLabs, Inc., which develops laboratory tests such as OneTest™, a multi‑cancer early detection blood test, and an expected "longevity test" focused on inflammatory biomarkers, as described in company news releases.

Longevity Health Holdings has also pursued transaction activity in the plasma and regenerative space. Company news and SEC filings reference the acquisition of Carmell Therapeutics and Elevai Skincare, and a later merger agreement with True Health Inc., which operates plasma collection centers under the THPlasma brand. The True Health transaction, as described in the company’s Form 8‑K and press releases, was structured as an all‑stock merger in which True Health would become a wholly owned subsidiary and the company would also acquire specified FDA‑related authorizations for True Health’s products. However, an 8‑K dated December 8, 2025 reports that the merger agreement with True Health was terminated after the merger was not consummated by November 30, 2025, with no termination fee payable by either party.

From a capital markets perspective, Longevity Health Holdings and its warrants have been listed on Nasdaq. The company implemented a 1‑for‑30 reverse stock split of its common stock, which became effective on May 12, 2025, with trading on a split‑adjusted basis beginning shortly thereafter under the symbol XAGE. Related disclosures note that proportional adjustments were made to the number of shares issuable upon exercise of outstanding stock options and warrants, and to applicable exercise prices. For the publicly traded warrants associated with XAGEW, SEC filings describe each whole warrant as exercisable for one share of common stock at a stated exercise price.

Subsequently, a Form 25 (25‑NSE) filed by Nasdaq Stock Market LLC on November 21, 2025, identifies Longevity Health Holdings, Inc. and specifies "Common Stock, Warrants" as the class of securities subject to removal from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. The filing indicates that the exchange complied with its rules to strike the class of securities from listing and/or withdraw registration on the exchange. This Form 25 is an official notice of delisting from Nasdaq for both the common stock and the warrants, although it does not address whether the securities trade on any other venue.

Throughout these developments, the company has used SEC filings and press releases to describe its focus on longevity, regenerative bio‑aesthetics, diagnostics, and nutrition, and to outline its transaction activity and listing status. Investors reviewing XAGEW should consider both the company’s stated product focus—particularly Carmell Secretome™ and Elevai Exosomes™ for skin and hair health—and the regulatory filings documenting capital markets actions such as the reverse stock split and Nasdaq delisting.

Business focus

Based on its own descriptions, Longevity Health Holdings positions itself around:

• Regenerative bio‑aesthetics for skin and hair health, using platelet‑derived and stem‑cell‑derived technologies.
• Diagnostics aimed at early detection and proactive management of chronic disease risk, through merger agreements and collaborations with entities such as 20/20 BioLabs.
• Nutrition and healthy aging as part of a broader "longevity and healthy aging" theme.

Capital markets and structure

Key structural and capital markets events described in the company’s disclosures include:

• A 1‑for‑30 reverse stock split of common stock, with split‑adjusted trading on Nasdaq under the symbol XAGE.
• Publicly traded redeemable warrants under the symbol XAGEW, each whole warrant exercisable for one share of common stock at an exercise price specified in SEC filings.
• A Form 25 filed by Nasdaq to remove the company’s common stock and warrants from listing and registration under Section 12(b).
• Merger and acquisition activity, including agreements with 20/20 BioLabs and True Health Inc., and the subsequent termination of the True Health merger agreement as disclosed in an 8‑K.

Status considerations

The Form 25 filing by Nasdaq documents that Longevity Health Holdings’ common stock and warrants, including XAGEW, were removed from listing and/or registration on Nasdaq. The filing itself does not state whether the securities trade on another market or over‑the‑counter, and no additional status beyond what appears in the provided filings can be inferred here. For historical and regulatory context, investors can review the company’s 8‑K filings describing the reverse stock split, merger agreements, and the termination of the True Health merger.